These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 25052852)

  • 21. Discovery of a novel noniminosugar acid α glucosidase chaperone series.
    Xiao J; Westbroek W; Motabar O; Lea WA; Hu X; Velayati A; Zheng W; Southall N; Gustafson AM; Goldin E; Sidransky E; Liu K; Simeonov A; Tamargo RJ; Ribes A; Matalonga L; Ferrer M; Marugan JJ
    J Med Chem; 2012 Sep; 55(17):7546-59. PubMed ID: 22834902
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Infantile Pompe disease: clinical and genetic characteristics with an experience of enzyme replacement therapy.
    Cho A; Kim SJ; Lim BC; Hwang H; Park JD; Kim GB; Jin DK; Lee J; Ki CS; Kim KJ; Hwang YS; Chae JH
    J Child Neurol; 2012 Mar; 27(3):319-24. PubMed ID: 21940687
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Determination of acid alpha-glucosidase activity in blood spots as a diagnostic test for Pompe disease.
    Umapathysivam K; Hopwood JJ; Meikle PJ
    Clin Chem; 2001 Aug; 47(8):1378-83. PubMed ID: 11468225
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Carnitine is a pharmacological allosteric chaperone of the human lysosomal
    Iacono R; Minopoli N; Ferrara MC; Tarallo A; Damiano C; Porto C; Strollo S; Roig-Zamboni V; Peluso G; Sulzenbacher G; Cobucci-Ponzano B; Parenti G; Moracci M
    J Enzyme Inhib Med Chem; 2021 Dec; 36(1):2068-2079. PubMed ID: 34565280
    [TBL] [Abstract][Full Text] [Related]  

  • 25. N-Butyl-l-deoxynojirimycin (l-NBDNJ): Synthesis of an Allosteric Enhancer of α-Glucosidase Activity for the Treatment of Pompe Disease.
    D'Alonzo D; De Fenza M; Porto C; Iacono R; Huebecker M; Cobucci-Ponzano B; Priestman DA; Platt F; Parenti G; Moracci M; Palumbo G; Guaragna A
    J Med Chem; 2017 Dec; 60(23):9462-9469. PubMed ID: 29112434
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pompe disease: dramatic improvement in gastrointestinal function following enzyme replacement therapy. A report of three later-onset patients.
    Bernstein DL; Bialer MG; Mehta L; Desnick RJ
    Mol Genet Metab; 2010; 101(2-3):130-3. PubMed ID: 20638881
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Improved assay for differential diagnosis between Pompe disease and acid α-glucosidase pseudodeficiency on dried blood spots.
    Shigeto S; Katafuchi T; Okada Y; Nakamura K; Endo F; Okuyama T; Takeuchi H; Kroos MA; Verheijen FW; Reuser AJ; Okumiya T
    Mol Genet Metab; 2011 May; 103(1):12-7. PubMed ID: 21320792
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Unwarranted, long term, alglucosidase alfa enzyme replacement therapy in two non-Pompe disease patients.
    Karam C; Ragole T; Moshe-Lilie O; Chahin N
    Clin Neurol Neurosurg; 2020 Sep; 196():106048. PubMed ID: 32623214
    [No Abstract]   [Full Text] [Related]  

  • 29. Targeted screening for the detection of Pompe disease in patients with unclassified limb-girdle muscular dystrophy or asymptomatic hyperCKemia using dried blood: A Spanish cohort.
    Gutiérrez-Rivas E; Bautista J; Vílchez JJ; Muelas N; Díaz-Manera J; Illa I; Martínez-Arroyo A; Olivé M; Sanz I; Arpa J; Fernández-Torrón R; López de Munáin A; Jiménez L; Solera J; Lukacs Z
    Neuromuscul Disord; 2015 Jul; 25(7):548-53. PubMed ID: 25998610
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacological enhancement of α-glucosidase by the allosteric chaperone N-acetylcysteine.
    Porto C; Ferrara MC; Meli M; Acampora E; Avolio V; Rosa M; Cobucci-Ponzano B; Colombo G; Moracci M; Andria G; Parenti G
    Mol Ther; 2012 Dec; 20(12):2201-11. PubMed ID: 22990675
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quantitative computed tomography for enzyme replacement therapy in Pompe disease.
    Yonee C; Toyoshima M; Young SP; Maruyama S; Higuchi I; Narita A; Maegaki Y; Nanba E; Ohno K; Kawano Y
    Brain Dev; 2012 Nov; 34(10):834-9. PubMed ID: 22521436
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pompe disease: current state of treatment modalities and animal models.
    Geel TM; McLaughlin PM; de Leij LF; Ruiters MH; Niezen-Koning KE
    Mol Genet Metab; 2007 Dec; 92(4):299-307. PubMed ID: 17826266
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cipaglucosidase Alfa: First Approval.
    Blair HA
    Drugs; 2023 Jun; 83(8):739-745. PubMed ID: 37184753
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ambulatory electrocardiogram analysis in infants treated with recombinant human acid alpha-glucosidase enzyme replacement therapy for Pompe disease.
    Cook AL; Kishnani PS; Carboni MP; Kanter RJ; Chen YT; Ansong AK; Kravitz RM; Rice H; Li JS
    Genet Med; 2006 May; 8(5):313-7. PubMed ID: 16702882
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 5-
    Kato A; Nakagome I; Kanekiyo U; Lu TT; Li YX; Yoshimura K; Kishida M; Shinzawa K; Yoshida T; Tanaka N; Jia YM; Nash RJ; Fleet GWJ; Yu CY
    J Med Chem; 2022 Feb; 65(3):2329-2341. PubMed ID: 35072486
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Screening for Pompe disease using a rapid dried blood spot method: experience of a clinical diagnostic laboratory.
    Goldstein JL; Young SP; Changela M; Dickerson GH; Zhang H; Dai J; Peterson D; Millington DS; Kishnani PS; Bali DS
    Muscle Nerve; 2009 Jul; 40(1):32-6. PubMed ID: 19533645
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Moss-Derived Human Recombinant GAA Provides an Optimized Enzyme Uptake in Differentiated Human Muscle Cells of Pompe Disease.
    Hintze S; Limmer S; Dabrowska-Schlepp P; Berg B; Krieghoff N; Busch A; Schaaf A; Meinke P; Schoser B
    Int J Mol Sci; 2020 Apr; 21(7):. PubMed ID: 32290314
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oral delivery of Acid Alpha Glucosidase epitopes expressed in plant chloroplasts suppresses antibody formation in treatment of Pompe mice.
    Su J; Sherman A; Doerfler PA; Byrne BJ; Herzog RW; Daniell H
    Plant Biotechnol J; 2015 Oct; 13(8):1023-32. PubMed ID: 26053072
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Advances in diagnosis and management of Pompe disease.
    Davison JE
    J Mother Child; 2020 Oct; 24(2):3-8. PubMed ID: 33554498
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Teaching tolerance: New approaches to enzyme replacement therapy for Pompe disease.
    Cousens LP; Mingozzi F; van der Marel S; Su Y; Garman R; Ferreira V; Martin W; Scott DW; De Groot AS
    Hum Vaccin Immunother; 2012 Oct; 8(10):1459-64. PubMed ID: 23095864
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.